Table 3.

Important results obtained during study

Patients with CHR (%)	78.04
Time to achieve CHR (weeks)	10.9
Patients with CCR (%)	12.2
Patients with MCR (%)	64.63
Patients with minor CR (%)	18.29
Patients with NCR (%)	4.88
Patients with cytopenias (any duration) requiring dose reduction (%)	43.9
Patients with cytopenias (>4 weeks) requiring dose reduction (%)	20.73
Mean TLC in patients with CCR (cells/mm3)	27,034
Mean TLC in patients with MCR (cells/mm3)	39,828
Mean TLC in patients with minor CR (cells/mm3)	66,764
Mean TLC in patients with NCR (cells/mm3)	72,102
Primary resistance to Imatinib (%)	4.88